BioMarin, Ascendis Settle Global Patent Dispute Over Yuviwel

SAN FRANCISCO (AP) — BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S have resolved a contentious global patent dispute concerning the growth hormone therapy Yuviwel by converting litigation into a royalty-bearing licensing agreement. The deal, finalized on Thursday, September 4, 2026, ends legal uncertainty that threatened to exclude the drug from major international markets.

Under the terms of the settlement, Ascendis Pharma will pay BioMarin royalties for the sale of Yuviwel in the United States, the European Union, Brazil, and South Korea. The agreement allows BioMarin to monetize its intellectual property without assuming the costs or risks associated with manufacturing or further clinical development of the therapy. For Ascendis, the resolution removes the immediate threat of injunctions that could have halted commercialization in these key territories.

The two biotechnology firms had been engaged in protracted legal battles over patent rights to Yuviwel, a treatment designed for children with growth hormone deficiency. The litigation created significant market volatility, as both companies faced the prospect of prolonged delays while courts determined ownership and validity of the underlying patents. By converting the dispute into a license, both parties avoid the substantial financial drain of continued courtroom proceedings.

Industry analysts note that the settlement structure benefits BioMarin by securing a revenue stream from a competitor's product while freeing up internal resources for its own pipeline. Ascendis gains immediate clarity on its market access strategy, allowing it to proceed with distribution plans in the four designated regions without fear of legal interruption. The agreement does not specify the royalty rate or the duration of the license, details typically kept confidential in such settlements.

The resolution marks a significant shift in the competitive landscape for pediatric endocrine therapies. Prior to this announcement, investors had grown concerned that extended litigation could erode market share for both companies as rival treatments gained traction. The settlement effectively neutralizes the legal barrier that had loomed over Yuviwel's expansion into emerging markets like Brazil and South Korea.

While the agreement resolves the immediate patent conflict, questions remain regarding the long-term commercial performance of Yuviwel in these newly secured markets. Additionally, it is unclear whether similar disputes involving other growth hormone therapies or related intellectual property could arise between the two companies in the future. Both firms have indicated they will focus on executing their respective business strategies following the conclusion of the legal standoff.